![1dd6b6387707d6ed528c40fc43633bcf 1dd6b6387707d6ed528c40fc43633bcf](https://utterbuzz.com/wp-content/uploads/2023/11/1dd6b6387707d6ed528c40fc43633bcf.jpg)
There’s officially a new and fierce competitor for Novo Nordisk’s Wegovy (semaglutide) when it comes to weight loss. On Wednesday, the Food and Drug Administration approved the drug tirzepatide, developed by Eli Lilly, as a treatment for obesity. The weekly injectable drug will be sold under the brand name Zepbound.